134 related articles for article (PubMed ID: 8390845)
21. A study of interactions among markers of macrophage functions in metastatic solid tumors: neopterin levels in relation to those of tumor necrosis factor-alpha and of soluble interleukin-2 receptors.
Lissoni P; Brivio F; Fumagalli L; Galimberti C; Cataldo M; Marsili MT; Brivio O; Barni S; Tancini G; Angelini A
J Biol Regul Homeost Agents; 1994; 8(1):32-5. PubMed ID: 7976492
[TBL] [Abstract][Full Text] [Related]
22. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
[TBL] [Abstract][Full Text] [Related]
23. Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil.
Clements PJ; Peter JB; Agopian MS; Telian NS; Furst DE
J Rheumatol; 1990 Jul; 17(7):908-10. PubMed ID: 2213757
[TBL] [Abstract][Full Text] [Related]
24. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
[TBL] [Abstract][Full Text] [Related]
25. Analysis of interleukin-2/interleukin-2 receptor system in advanced non-small-cell lung cancer.
De Vita F; Turitto G; di Grazia M; Frattolillo A; Catalano G
Tumori; 1998; 84(1):33-8. PubMed ID: 9619711
[TBL] [Abstract][Full Text] [Related]
26. Low-dose total body irradiation augments the therapeutic effect of interleukin-2 in a mouse model for metastatic malignant melanoma.
Safwat A; Aggerholm N; Roitt I; Overgaard J; Hokland M
J Exp Ther Oncol; 2003; 3(4):161-8. PubMed ID: 14567287
[TBL] [Abstract][Full Text] [Related]
27. Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma.
Aldeghi R; Lissoni P; Barni S; Ardizzoia A; Tancini G; Piperno A; Pozzi M; Ricci G; Conti A; Maestroni GJ
Eur J Cancer; 1994; 30A(2):167-70. PubMed ID: 8155391
[TBL] [Abstract][Full Text] [Related]
28. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
29. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
30. Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors.
Lissoni P; Rovelli F; Tisi E; Brivio F; Ardizzoia A; Barni S; Tancini G; Saudelli M; Cesana E; Viganò MG
J Biol Regul Homeost Agents; 1995; 9(4):146-9. PubMed ID: 8844339
[TBL] [Abstract][Full Text] [Related]
31. Influence of immunotherapy (IL2 + LAK + inhibition of prostaglandin synthesis) on peripheral blood immune parameters and in vitro cytokine production in metastatic renal cell carcinoma.
Kleinknecht S; Bichler KH; Strohmaier WL
Urol Int; 1993; 50(3):121-8. PubMed ID: 8465478
[TBL] [Abstract][Full Text] [Related]
32. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis.
Ott M; Demisch L; Engelhardt W; Fischer PA
J Neurol; 1993 Dec; 241(2):108-14. PubMed ID: 8138825
[TBL] [Abstract][Full Text] [Related]
34. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
35. Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients.
Lissoni P; Mengo S; Bucovec R; Brivio F; Fumagalli L; Tancini G; Gardani GS
In Vivo; 2003; 17(1):73-5. PubMed ID: 12655794
[TBL] [Abstract][Full Text] [Related]
36. Effects of interleukin-2 immunotherapy on soluble lymphocyte markers in cancer patients.
Lissoni P; Rovelli F; Tisi E; Ballabio D; Benenti C; Ardizzoia A; Barni S; Tancini B
Int J Biol Markers; 1992; 7(4):260-2. PubMed ID: 1337089
[No Abstract] [Full Text] [Related]
37. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G
Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
[TBL] [Abstract][Full Text] [Related]
38. Amplification of eosinophilia by melatonin during the immunotherapy of cancer with interleukin-2.
Lissoni P; Ardizzoia A; Tisi E; Rossini F; Barni S; Tancini G; Conti A; Maestroni GJ
J Biol Regul Homeost Agents; 1993; 7(1):34-6. PubMed ID: 8346714
[TBL] [Abstract][Full Text] [Related]
39. Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with solid tumors.
Orditura M; De Vita F; Roscigno A; Auriemma A; Infusino S; Catalano G
Int J Mol Med; 1998 Jul; 2(1):75-9. PubMed ID: 9854147
[TBL] [Abstract][Full Text] [Related]
40. Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2.
Gooding R; Riches P; Dadian G; Moore J; Gore M
Br J Cancer; 1995 Aug; 72(2):452-5. PubMed ID: 7640231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]